ArticleGene therapy2024

Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery.

Sarah Klinnert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.